Journal
CNS NEUROSCIENCE & THERAPEUTICS
Volume 28, Issue 12, Pages 2218-2229Publisher
WILEY
DOI: 10.1111/cns.13965
Keywords
ADNI; Alzheimer's disease; amyloid-beta; p75NTR; polymorphism
Categories
Funding
- National Natural Science Foundation of China [81870860, 81625007]
- Alzheimer's Disease Neuroimaging Initiative (ADNI)) (National Institutes of Health) [U01 AG024904]
- DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- AbbVie
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Araclon Biotech
- BioClinica, Inc.
- Biogen
- Bristol-Myers Squibb Company
- CereSpir, Inc.
- Cogstate
- Eisai Inc.
- Elan Pharmaceuticals, Inc.
- Eli Lilly and Company
- EuroImmun
- F. Hoffmann--La Roche Ltd
- Genentech, Inc.
- Fujirebio
- GE Healthcare
- IXICO Ltd.
- Janssen Alzheimer Immunotherapy Research & Development,LLC.
- Johnson & Johnson Pharmaceutical Research & Development LLC.
- Meso Scale Diagnostics, LLC.
- NeuroRx Research
- Neurotrack Technologies
- Novartis Pharmaceuticals Corporation
- Servier
- Takeda Pharmaceutical Company
- Transition Therapeutics
- The Canadian Institutes of Health Research
- Lumosity
- Lundbeck
- Merck Co., Inc.
- Pfizer Inc.
- Piramal Imaging
Ask authors/readers for more resources
This study analyzed the relationship between NGFR gene polymorphism and the risk of Alzheimer's disease (AD) in the Chinese Han population and the association of a tag-SNP (rs2072446) with amyloid-beta deposition in the ADNI cohort.
Introduction and Aims: Alzheimer's disease (AD) is the most common form of dementia with a complex genetic background. The cause of sporadic AD (sAD) remains largely unknown. Increasing evidence shows that genetic variations play a crucial role in sAD. P75 neurotrophin receptor (p75NTR, encoded by NGFR) plays a critical role in the pathogenesis of AD. Yet, the relationship between NGFR gene polymorphisms and AD was less studied. This study aims to analyze the relationship of NGFR gene polymorphism with the risk of AD in the Chinese Han population and amyloid-beta deposition in the ADNI cohort. Methods: This case-control association study was conducted in a Chinese Han cohort consisting of 366 sporadic AD (sAD) patients and 390 age- and sex-matched controls. Twelve tag-SNPs were selected and genotyped with a multiplex polymerase chain reaction-ligase detection reaction (PCR-LDR) method. The associations between tag-SNPs and the risk of AD were analyzed by logistic regression. Moreover, another cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database was included to examine the association of one tag-SNP (rs2072446) with indicators of amyloid deposition. Kaplan-Meier survival analysis and Cox proportional hazards models were used to test the predictive abilities of rs2072446 genotypes for AD progression. The mediation effects of A beta deposition on this association were subsequently tested by mediation analyses. Results: After multiple testing corrections, one tag-SNP, rs2072446, was associated with an increased risk of sAD (additive model, OR = 1.79, P-adjustment = 0.0144). Analyses of the ADNI cohort showed that the minor allele (T) of rs2072446 was significantly associated with the heavier A beta burden, which further contributed to an increased risk of AD progression in APOE epsilon 4 non-carrier. Conclusion: Our study found that rs2072446 in NGFR is associated with both the risk of sAD in the Chinese Han population and the amyloid burden in the ADNI cohort, which reveals the role of p75NTR in AD from a genetic perspective.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available